Ertapenem SUN Եվրոպական Միություն - սլովեներեն - EMA (European Medicines Agency)

ertapenem sun

sun pharmaceutical industries (europe) b.v. - ertapenem natrij - bakterijske okužbe - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 in 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Teriparatide Sun Եվրոպական Միություն - սլովեներեն - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - kalcij homeostaza - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Vyxeos liposomal (previously known as Vyxeos) Եվրոպական Միություն - սլովեներեն - EMA (European Medicines Agency)

vyxeos liposomal (previously known as vyxeos)

jazz pharmaceuticals ireland limited - daunorubicin hydrochloride, cytarabine - leukemija, myeloid, akutna - antineoplastična sredstva - vyxeos liposomal je indiciran za zdravljenje odraslih z novo diagnozo, terapijo, povezanih z akutno mieloično levkemijo (t-aml) ali aml z myelodysplasia povezane spremembe (aml-mrc).

Nyxthracis (previously Obiltoxaximab SFL) Եվրոպական Միություն - սլովեներեն - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imunski sera in imunoglobulini, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Sitagliptin / Metformin hydrochloride Sun Եվրոպական Միություն - սլովեներեն - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Escitalopram Teva 10 mg filmsko obložene tablete Սլովենիա - սլովեներեն - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

escitalopram teva 10 mg filmsko obložene tablete

teva pharma b.v. - escitalopram - filmsko obložena tableta - escitalopram 10 mg / 1 tableta - escitalopram

Escitalopram Teva 20 mg filmsko obložene tablete Սլովենիա - սլովեներեն - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

escitalopram teva 20 mg filmsko obložene tablete

teva pharma b.v. - escitalopram - filmsko obložena tableta - escitalopram 20 mg / 1 tableta - escitalopram

Escitalopram Teva 15 mg filmsko obložene tablete Սլովենիա - սլովեներեն - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

escitalopram teva 15 mg filmsko obložene tablete

teva pharma b.v. - escitalopram - filmsko obložena tableta - escitalopram 15 mg / 1 tableta - escitalopram

Escitalopram Teva 5 mg filmsko obložene tablete Սլովենիա - սլովեներեն - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

escitalopram teva 5 mg filmsko obložene tablete

teva pharma b.v. - escitalopram - filmsko obložena tableta - escitalopram 5 mg / 1 tableta - escitalopram

Cabometyx Եվրոպական Միություն - սլովեներեն - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastična sredstva - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.